Hemofarm a.d.
 Official logo | |
Native name | Хемофарм |
|---|---|
| Company type | Joint-stock company |
| Industry | Pharmaceuticals |
| Founded | 28 August 1998 (current form) 1960 (founded) |
| Headquarters | Beogradski put bb, Vršac ,Serbia |
Key people | Ronald Seeliger (CEO) |
| Products | Pharmaceuticals, Prescription drugs |
| Revenue |  €337.37 million (2018)[1] |
| €26.47 million (2018)[1] | |
| Total assets | €436.09 million (2018)[2] |
| Total equity | €296.34 million (2018)[2] |
| Owner | STADA (100%) |
Number of employees | 3,134 (2018) |
| Website | www |
Hemofarm a.d. (full legal name: Hemofarm a.d. Farmaceutsko-hemijska industrija Vršac), a member of STADA Group, is a Serbian pharmaceutical company based in Vršac, Serbia. Founded in 1960, it is one of the largest domestic producer and exporter of medicines in Serbia. Hemofarm currently operates in more than 30 countries on 3 continents and has around 3,000 employees.
The core activity represents the manufacture of Rx and OTC medicines and products. The portfolio includes over 140 INNs,[clarification needed] with about 280 forms and dosage forms.
History
Hemofarm was established on 1 June 1960 in Vršac. In 2003, it opened the first factory for the production of medicine in entity Republika Srpska, Bosnia and Herzegovina. As of 2003, Hemofarm consisted of 21 subsidiaries, 12 of which were located in Serbia and the rest in Montenegro.[3]
In 2004, the company acquired four other Serbian concerns, increasing its market share from 15% to 45% in the process.[4] As of 2011, the company has a market share in terms of production and import of 30.7%.[5]
Hemofarm was bought by the German STADA Arzneimittel pharmaceutical group for 480 million euros in 2006.[6] Since 9 August 2009 Hemofarm has been a member of the German STADA Group.[citation needed]
In August 2016, Hemofarm bought the assets of a Serbian minor pharmaceutical company "Ivančić i sinovi" for undisclosed amount.[7]
Research and development
Hemofarm’s R&D division was established in 1990, and it has been recognized by STADA as a competence center for development of new generic products not only for local and regional markets, but also for the whole STADA Group. An intensive development of products intended for registration and sale in the demanding European Union market started in 2007.[citation needed]
References
- ^ a b "КОНСОЛИДОВАНИ БИЛАНС УСПЕХА (2018) - Хемофарм". apr.gov.rs (in Serbian). Retrieved 28 September 2019.
- ^ a b "КОНСОЛИДОВАНИ БИЛАНС СТАЊА (2018) - Хемофарм". apr.gov.rs. Retrieved 28 September 2019.
- ^ "Bosnian Serb, Serbian premiers inaugurate pharmaceutical plant". Asia Africa Intelligence Wire. February 21, 2003. Retrieved 2008-10-02.
- ^ Doing Business with Serbia By Marat Terterov, Consultant Editor, Marat Terterov, Inc NetLibrary; Published by GMB Publishing Ltd, 2006; ISBN 1-905050-68-2, ISBN 978-1-905050-68-0.
- ^ Lazarević, Igor. "Konsolidacija farmaceutskog tržišta Srbije". scribd.com (in Serbian). Retrieved 28 July 2014.
- ^ "Stada Says Strength of Russian Unit May Attract Bids". Blommberg. 11 January 2013. Retrieved 9 April 2013.
- ^ Popadić, Jelena (25 September 2016). "Ko je kupio "Ivančić i sinove"". politika.rs (in Serbian). Retrieved 13 March 2018.